Kinnate Biopharma Inc. (KNTE)
NASDAQ: KNTE
· Real-Time Price · USD
2.65
-0.01 (-0.38%)
At close: Apr 02, 2024, 10:00 PM
Kinnate Biopharma Income Statement
Financials in USD. Fiscal
year is
January - December.
| Fiscal Year | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 | Q3 2021 | Q2 2021 | Q1 2021 |
| Period Ending | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 |
Revenue | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Cost of Revenue | 799K | 791K | 778K | 749K | 546K | 356K | 172K | n/a | n/a | n/a | n/a | n/a |
Gross Profit | -799K | -791K | -778K | -749K | -546K | -356K | -172K | n/a | n/a | n/a | n/a | n/a |
Operating Income | -120.98M | -134.56M | -132.84M | -126.11M | -118.52M | -112.1M | -105.53M | -99.69M | -90.11M | -77.57M | -63.27M | -49.33M |
Interest Income | 2.24M | 1.12M | 1.12M | 1.12M | 1.12M | 248.00 | 640.25K | 1.31M | 1.72M | 1.73M | 1.1M | 436K |
Pretax Income | -112.65M | -127.15M | -127.16M | -122.31M | -116.27M | -110.87M | -104.83M | -99.21M | -89.76M | -77.31M | -63.11M | -49.28M |
Net Income | -110.94M | -123.83M | -123.19M | -118.01M | -113.53M | -109.74M | -104.34M | -99.05M | -89.76M | -77.31M | -63.11M | -49.28M |
Selling & General & Admin | 28.04M | 30M | 31.22M | 31.05M | 30.37M | 29.61M | 27.85M | 25.54M | 22.95M | 17.96M | 13.9M | 10.62M |
Research & Development | 90.77M | 102.58M | 101.62M | 95.06M | 88.15M | 82.49M | 77.67M | 74.15M | 67.17M | 59.61M | 49.37M | 38.7M |
Other Expenses | 1.97M | 1.97M | n/a | n/a | 157K | 157K | 157K | 157K | n/a | n/a | n/a | n/a |
Operating Expenses | 120.78M | 134.56M | 132.84M | 126.11M | 118.52M | 112.1M | 105.53M | 99.69M | 90.11M | 77.57M | 63.27M | 49.33M |
Interest Expense | n/a | 494K | 494K | 494K | 494K | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Selling & Marketing Expenses | -198K | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Cost & Expenses | 120.98M | 134.56M | 132.84M | 126.11M | 118.52M | 112.1M | 105.53M | 99.69M | 90.11M | 77.57M | 63.27M | 49.33M |
Income Tax Expense | -1.91M | -3.52M | -3.96M | -4.3M | -2.74M | -1.12M | -482K | -145K | 12K | n/a | n/a | n/a |
Shares Outstanding (Basic) | 47.12M | 47.09M | 46.66M | 45.41M | 44.21M | 44.15M | 44M | 43.88M | 43.66M | 43.66M | 43.54M | 43.48M |
Shares Outstanding (Diluted) | 47.12M | 47.09M | 46.66M | 45.41M | 44.21M | 44.15M | 44M | 43.88M | 43.66M | 43.66M | 43.54M | 43.48M |
EPS (Basic) | -2.38 | -2.7 | -2.73 | -2.66 | -2.58 | -2.5 | -2.39 | -2.27 | -2.06 | -1.77 | -1.46 | -1.15 |
EPS (Diluted) | -2.38 | -2.7 | -2.73 | -2.66 | -2.58 | -2.5 | -2.39 | -2.27 | -2.06 | -1.77 | -1.46 | -1.15 |
EBITDA | -120.38M | -133.97M | -132.07M | -125.37M | -117.92M | -111.65M | -105.23M | -99.54M | -89.99M | -77.46M | -63.17M | -49.23M |
EBIT | -120.98M | -132.95M | -131.23M | -124.5M | -116.91M | -112.1M | -105.53M | -99.69M | -90.11M | -77.57M | -63.27M | -49.33M |
Depreciation & Amortization | 799K | 791K | 778K | 749K | 604K | 450K | 294K | 150K | 123K | 111K | 106K | 98K |